72 related articles for article (PubMed ID: 18710373)
1. The antidepressant sertraline downregulates Akt and has activity against melanoma cells.
Reddy KK; Lefkove B; Chen LB; Govindarajan B; Carracedo A; Velasco G; Carrillo CO; Bhandarkar SS; Owens MJ; Mechta-Grigoriou F; Arbiser JL
Pigment Cell Melanoma Res; 2008 Aug; 21(4):451-6. PubMed ID: 18710373
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice.
Gil-Ad I; Zolokov A; Lomnitski L; Taler M; Bar M; Luria D; Ram E; Weizman A
Int J Oncol; 2008 Aug; 33(2):277-86. PubMed ID: 18636148
[TBL] [Abstract][Full Text] [Related]
3. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival.
Karst AM; Dai DL; Cheng JQ; Li G
Cancer Res; 2006 Sep; 66(18):9221-6. PubMed ID: 16982766
[TBL] [Abstract][Full Text] [Related]
4. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
[TBL] [Abstract][Full Text] [Related]
5. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity.
Shin SW; Seo CY; Han H; Han JY; Jeong JS; Kwak JY; Park JI
Clin Cancer Res; 2009 Sep; 15(17):5414-25. PubMed ID: 19690198
[TBL] [Abstract][Full Text] [Related]
6. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
[TBL] [Abstract][Full Text] [Related]
8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
9. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis.
Tang C; Lu YH; Xie JH; Wang F; Zou JN; Yang JS; Xing YY; Xi T
Anticancer Drugs; 2009 Apr; 20(4):249-58. PubMed ID: 19174695
[TBL] [Abstract][Full Text] [Related]
11. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
12. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
13. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical assessment of A-674563 as an anti-melanoma agent.
Zou Y; Fan G; Wang X
Biochem Biophys Res Commun; 2016 Aug; 477(1):1-8. PubMed ID: 26970307
[TBL] [Abstract][Full Text] [Related]
15. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
Ji YB; Zhou JH; Zuo MX; You QD
Yao Xue Xue Bao; 2008 Aug; 43(8):811-8. PubMed ID: 18956773
[TBL] [Abstract][Full Text] [Related]
16. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma.
Pellizzari Tregno F; Sau A; Pezzola S; Geroni C; Lapenta C; Spada M; Filomeni G; Bonanno E; Federici G; Caccuri AM
Eur J Cancer; 2009 Sep; 45(14):2606-17. PubMed ID: 19665369
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma.
De Stefano I; Raspaglio G; Zannoni GF; Travaglia D; Prisco MG; Mosca M; Ferlini C; Scambia G; Gallo D
Biochem Pharmacol; 2009 Dec; 78(11):1374-81. PubMed ID: 19643088
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.
Yan D; Zhou X; Chen X; Hu DN; Dong XD; Wang J; Lu F; Tu L; Qu J
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1559-65. PubMed ID: 19029026
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
